BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that its ErbB-2 / EGFR inhibitor, ARRY-543, produced stable disease in refractory patients with advanced solid tumors in a Phase 1 clinical trial. The results were presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by Mace Rothenberg, M.D., Ingram Professor of Cancer Research, Vanderbilt-Ingram Cancer Center. The poster is also available as a PDF on Array’s website at www.arraybiopharma.com.
